Which blockbuster products could drive the CSL share price higher?

What's going on behind the scenes in the labs of CSL?

| More on:
Two lab technicians wearing white coats discuss results they see on a computer screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the last 10 years, the CSL Limited (ASX: CSL) share price has absolutely smashed the market.

During this time, the biotherapeutics giant's shares have posted an average total return of 18.58% per annum.

To put this into context, this would have turned a $10,000 investment into approximately $55,000.

Why has the CSL share price smashed the market?

Investors have been bidding the CSL share price higher over the last 10 years thanks to its consistently strong earnings growth.

There have been a few key drivers of this impressive growth. Strong demand for CSL's existing therapies, earnings accretive acquisitions, and its lucrative research and development (R&D) pipeline.

The latter is underpinned by a material investment in R&D activities each year by management. And when I say material, I mean it.

Each year, the company reinvests in the region of 11% of its sales back into R&D. This meant an investment of over US$1 billion in FY 2022.

The good news is that this investment means there are plenty of potentially lucrative products on the way that could be the next drivers of growth. But what are they?

What will drive CSL's future growth?

Late last year, Citi commented on CSL's R&D event and highlighted CSL112 as one of the most important products under development. It commented:

The R&D budget is significant at US$1.16bn in FY22 or ~11% of revenue. CSL will continue to spend ~10-11% of revenue on R&D annually. The pipeline now includes assets from recently acquired Vifor with two assets in Phase 3. Our $340 [now $350] TP includes $22.40 for the R&D portfolio (down from $23 on delays) – the main asset remains CSL112 (cardiovascular) at $20/share on which we will get Phase 3 data in Q1 CY24. Maintain Buy, $340 TP.

What is CSL112? It is a novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI). Completion of the trial is expected by the end of the year, which means that, if all goes to plan, it may not be too long until this therapy is generating revenue for CSL.

And what a lot of revenue it could generate! Some analysts estimate that CSL112 could pull in peak sales of US$3 billion. That compares to CSL's total FY 2022 sales of approximately US$10.13 billion.

What else?

And then there's CSL312, also known as garadacimab. This upcoming product has been described as a pipeline within a product by analysts at Goldman Sachs. It explains:

CSL312 is a humanised anti-factor XIIa monoclonal antibody in development for multiple indications including as a subcutaneous therapy for HAE [hereditary angioedema], with the potential for administration every 4 weeks (vs. every 2-3 days for Haegarda). Given its early position in the coagulation cascade, there is also potential application in various other disorders (including fibrosis, cardiovascular and inflammatory indications).

Catherine Milch, CSL's Vice President R&D Immunology, thinks very highly of the product. Milch said:

Based on the data published in The Lancet, we believe garadacimab has the potential to become a transformative first-in-class therapy, providing a new option where there is significant unmet need. The development of garadacimab reflects our commitment to providing life changing medicines for patients with HAE and for the physicians who treat them.

Overall, the future looks bright for CSL and its share price. Especially when you consider that the above are just two of a large (and growing) number of products in its pipeline.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »